Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda announces phase II Hematide results

Takeda announces phase II Hematide results

6th November 2007

Takeda Pharmaceutical and Affymax have announced the results from a phase II clinical study of Hematide as a treatment of anaemia in dialysis and predialysis patients with chronic kidney disease and pure red cell aplasia (PRCA).

Presented at the renal week of the American Society of Nephrology, the results showed that the compound can restore haemoglobin to the target range in these patients, removing the need for transfusions of red blood cells.

Hematide is an innovative, synthetic pegylated peptidic compound that acts as an erythropoiesis stimulating agent by binding to and activating the erythropoietin receptor.

Masaomi Miyamoto, general manager of pharmaceutical development division at Takeda, said: “With our partner Affymax, we will vigorously continue development activities of this scientifically interesting product as a potential new treatment option for patients with anaemia in both chronic renal failure and chemotherapy-induced anaemia.”

He added that the company is pleased with the recent presentation of data which show the distinctness of Hematide and currently available recombinant human erythropoietin.

Last month, Takeda and Affymax were awarded the 2007 Deal of Distinction accolade from the Licensing Executives Society of the US and Canada for their global development and marketing deal for Hematide.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.